利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.015 秒)

    Immuno-dye reagent and assay for detection of endotoxin
    3.
    发明授权
    Immuno-dye reagent and assay for detection of endotoxin 失效
    免疫染色试剂和检测内毒素检测

    公开(公告)号：US5093235A

    公开(公告)日：1992-03-03

    申请号：US414224

    申请日：1989-09-29

    申请人： Taffy J. Williams ,  Che-Hung Lee ,  Akindele O. Johnson

    发明人： Taffy J. Williams ,  Che-Hung Lee ,  Akindele O. Johnson

    IPC分类号： G01N33/569 ,  G01N33/579

    CPC分类号： G01N33/56916 ,  G01N33/579 ,  Y10S435/975 ,  Y10S436/808 ,  Y10S436/815

    摘要： A novel immuno-dye reagent capable of detecting the presence of endotoxin in samples has been developed. The immuno-dye reagent comprises a solution of new methylene blue and an anti-endotoxin monoclonal antibody specific to a selected endotoxin. The immuno-dye reagent can be used in an assay to detect endotoxin by reacting the immuno-dye reagent with an endotoxin suspect pH adjusted sample, under hydrophobic conditions. The immuno-dye reagent can also be used in any application where binding of endotoxin is crucial, such as purifying endotoxin-contaminated solutions.

    摘要翻译： 已经开发了能够检测样品中内毒素的存在的新型免疫染料试剂。 免疫染料试剂包含新的亚甲基蓝和对选择的内毒素特异性的抗内毒素单克隆抗体的溶液。 免疫染料试剂可用于通过在疏水条件下使免疫染料试剂与内毒素可疑pH调节的样品反应来检测内毒素。 免疫染料试剂也可以用于内毒素结合至关重要的任何应用，例如净化内毒素污染的溶液。

    Biologically active peptides with reduced toxicity in animals and a method for preparing same
    4.
    发明授权
    Biologically active peptides with reduced toxicity in animals and a method for preparing same 失效
    动物毒性降低的生物活性肽及其制备方法

    公开(公告)号：US06348445B1

    公开(公告)日：2002-02-19

    申请号：US09115737

    申请日：1998-07-15

    申请人： U. Prasad Kari ,  Taffy J. Williams ,  Michael McLane

    发明人： U. Prasad Kari ,  Taffy J. Williams ,  Michael McLane

    IPC分类号： A61K3800

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/001 ,  C07K14/435 ,  C07K14/43563 ,  C07K14/46 ,  C07K14/463

    摘要： The present invention relates to biologically active peptides with reduced toxicity and methods of preparing them. The peptides of the invention, which can be unsubstituted or N-terminal substituted have the formula: wherein X is a biologically active amphiphilic ion channel-forming peptide or protein, T is a lipophilic moiety or hydrogen, and W is T or hydrogen. Preferably T is: wherein R is a hydrocarbon (alkyl or aromatic or alkylaromatic) having at least 2 and no more than 10 carbon atoms. T is preferably an octanoyl group. The peptides and proteins of the invention have improved antimicrobial and anti-tumor biological activity while exhibiting reduced toxicity. A preferred method of reducing toxicity involves the formation of related methane sulfonate derivatives or analogues. Additionally, the compounds of the invention may be used to treat sepsis, septic shock, and lung infections, such as those occurring in cystic fibrosis.

    摘要翻译： 本发明涉及毒性降低的生物活性肽及其制备方法。 可以是未取代或N-末端取代的本发明的肽具有下式：其中X是生物活性两亲离子通道形成肽或蛋白质，T是亲脂性部分或氢，W是T或氢。 T优选：其中R是具有至少2个且不超过10个碳原子的烃（烷基或芳族或烷基芳族）。 T优选为辛酰基。 本发明的肽和蛋白质具有改善的抗微生物和抗肿瘤生物活性，同时显示降低的毒性。 降低毒性的优选方法涉及形成相关的甲磺酸衍生物或类似物。 此外，本发明的化合物可用于治疗败血症，败血性休克和肺部感染，例如发生在囊性纤维化中的那些。

    METHODS FOR VASCULAR IMAGING USING NANOPARTICULATE CONTRAST AGENTS
    6.
    发明申请
    METHODS FOR VASCULAR IMAGING USING NANOPARTICULATE CONTRAST AGENTS 审中-公开
    使用纳米颗粒对比剂进行血管成像的方法

    公开(公告)号：US20100055032A1

    公开(公告)日：2010-03-04

    申请号：US12487349

    申请日：2009-06-18

    申请人： Reinhard Koenig ,  Taffy J. Williams

    发明人： Reinhard Koenig ,  Taffy J. Williams

    IPC分类号： A61K51/00 ,  A61K49/00 ,  A61K49/04

    CPC分类号： B82Y5/00 ,  A61B6/507 ,  A61B6/508 ,  A61K49/0485

    摘要： New and sensitive methods for imaging the perfusion of tissues and the extravasation of blood out vessels have been developed. The present invention is useful in the imaging of microperfusion in organ tissues (e.g., heart, liver, brain and kidneys) to aid in evaluating the perfusion status of organs on the level of the smallest blood vessels (i.e. capillaries). The present invention also provides methods and compositions for imaging and evaluating macrophages and plaque, e.g., vulnerable plaque. Such evaluations are important in a number of clinical diagnoses, including assessing organ damage associated with angina pectoris, heart attack, stroke, and the like, as well as assessing vessel leakages associated with aneurisms, diffuse bleedings after trauma, and the like.

    摘要翻译： 已经开发了用于成像灌注组织和血液外渗血管的新的和敏感的方法。 本发明可用于器官组织（例如心脏，肝，脑和肾）中微灌注的成像，以帮助评估器官在最小血管（即毛细血管）水平上的灌注状态。 本发明还提供用于成像和评价巨噬细胞和斑块（例如易损斑块）的方法和组合物。 这样的评估在许多临床诊断中是重要的，包括评估与心绞痛相关的器官损伤，心脏病发作，中风等，以及评估与动脉瘤相关的血管渗漏，创伤后扩散出血等。

    Non-aqueous colonic purgative formulations
    7.
    发明授权
    Non-aqueous colonic purgative formulations 失效
    非水结肠泻药配方

    公开(公告)号：US6162464A

    公开(公告)日：2000-12-19

    申请号：US829080

    申请日：1997-03-31

    申请人： Leonard S. Jacob ,  Taffy J. Williams ,  Robert D. Krell

    发明人： Leonard S. Jacob ,  Taffy J. Williams ,  Robert D. Krell

    IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/12 ,  A61K31/122 ,  A61K31/19 ,  A61K31/194 ,  A61K31/235 ,  A61K33/04 ,  A61K33/06 ,  A61K33/08 ,  A61K33/10 ,  A61K33/14 ,  A61K33/42 ,  A61P1/00 ,  A61P1/10

    CPC分类号： A61K33/42 ,  A61K31/19 ,  A61K33/04 ,  A61K33/06 ,  A61K33/14

    摘要： Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg.sub.3 (PO.sub.4).sub.2, MgHPO.sub.4, Mg(H.sub.2 PO.sub.4).sub.2, MgSO.sub.4, MgCl.sub.2, Na.sub.2 SO.sub.4, sodium tartrate, potassium tartrate, magnesium tartrate and mixtures, thereof, administered in tablet or capsule form in purgative effective concentrations. Preferred embodiments make use of at least one or more magnesium phosphate salts, more preferably dibasic magnesium phosphate; other preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.

    摘要翻译： 口服施用的结肠泻药制剂及其用于在哺乳动物中部分或完全清除结肠的方法，所述制剂由选自Mg 3（PO 4）2，MgHPO 4，Mg（ H 2 PO 4）2，MgSO 4，MgCl 2，Na 2 SO 4，酒石酸钠，酒石酸钾，酒石酸钾及其混合物，以片剂或胶囊形式以泻药有效浓度给药。 优选的实施方案使用至少一种或多种磷酸镁盐，更优选磷酸氢二钙; 其它优选的实施方案包括添加粘合剂，分散剂和缓冲液，其不会不利地影响泻药制剂的重量摩尔渗透压浓度或有效性。